Scientists have discovered an enzyme that could make popular drugs like Ozempic and Wegovy last longer and work faster — potentially supercharging diabetes and weight-loss treatments.

The enzyme called PapB works by “tying off” peptide drugs into tight ring shapes through a process called macrocyclization, making them tougher and more resistant to breaking down in the body, according to researchers at the University of Utah, who published their findings in ACS Publications.

Peptides are powerful, and forming them into rings is especially valuable because these structures improve stability, extend how long drugs remain active in the body, and can enhance how effectively they interact with biological targets, according to co-author Karsten Eastman.

The bottom line means drugs with stronger, longer-lasting effects, say the researchers.

“Big pharma’s GLP-1 backbones are already excellent,” Eastman said. “What we’re adding is a clean, late-state enzymatic step that can make those molecules work even harder.”

Researchers are not only excited about what this could mean for blockbuster drugs like Ozempic, but also for other peptide-based drugs that treat gastrointestinal diseases and cancer tumors.

Ozempic and Wegovy are injectable drugs that mimic a natural hormone to suppress appetite, slow digestion and lower blood sugar — helping patients manage Type 2 diabetes or lose significant weight, respectively.